Clinical Trial Update: Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing pembrolizumab with dual MAPK pathway inhibition plus pembrolizumab in metastatic melanoma is reported as ongoing with unknown sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Metastatic Melanoma | Phase 2 | Status: UNKNOWN